Sam Wolfe-Murray is an associate in the London office of Gibson Dunn and is a member of the Private Equity and Mergers and Acquisitions Practice Groups.
Sam has broad experience in private equity and M&A transactions, including leveraged buyouts, strategic acquisitions, growth equity, preferred equity, convertible instruments, secondary transactions, co-investments, and other minority investments.
Prior to joining Gibson Dunn, Sam worked in the London private equity team of another global elite law firm. Before that, Sam trained and qualified at a UK magic circle firm into their private equity team, studied law at the University of Oxford, worked with family offices on early stage investments, and studied chemistry at the University of Sydney.
Sam’s experience includes: *
- Advised 65 Equity Partners on its investment in HAS Healthcare Advanced Synthesis SA’s, and HAS’s planned acquisition of Cerbios-Pharma SA, a globally recognised manufacturer of chemical and biological APIs
- Advised American Industrial Partners on its acquisition of an ownership position in Aker BioMarine's Feed Ingredients segment
- Advised Bain Capital in relation to the sale of a stake in Beat Capital Partners to Ambac Financial Group
- Advised Audax Strategic Capital on undisclosed multiple convertible preferred investments into UK and US-based businesses
- Advised Mitsubishi UFJ Financial Group (MUFG) subsidiary Mitsubishi UFJ Trust and Banking Corporation on the UK aspects of its acquisition of leading Australian pension administration firm Link Group (LNK.AX) in a A$1.2 billion (US$802.7 million) deal, as Japan's largest banking group continues to grow its fund administration business
- Advised American Industrial Partners on its acquisition of AquaShip AS, a leading aqua service vessel provider, and subsequent acquisition and combination of Intership, another aqua service business
- Advised Pfizer on its $25m strategic investment in CellCentric
- Advised Becton, Dickinson and Company in its acquisition of Tissuemed Ltd, a developer of surgical sealant technology
- Advised Partners Group on its acquisition of Pharmathen, a European pharmaceutical company, from international investment firm BC Partners on behalf of its clients. The transaction values Pharmathen at an enterprise value of around EUR1.6 billion
- Advised Avista Capital Partners and Nordic Capital and Swiss pharmaceutical company Acino on the sale of Acino to ADQ
- Advised CVC Capital Partners on their investment alongside the International Federation of Volleyball (FIVB), into VW Volleyball World SA, a newly incorporated commercial entity holding the commercial rights to volleyball
- Advised CVC Capital Partners on their investment into Premiership Rugby Limited
- Advised CVC Capital Partners on their minority investment into Pro14, the rugby competition
- Advised Barings and M&G on their investment into Tunstall Healthcare, a leading global provider of software solutions and services for the telecare and telehealth markets by way of restructuring and recapitalisation
- Advised Hellman & Friedman on the €7.8 billion all share merger of Nets, a leading payments provider, into Nexi, a leading payments technology company in Italy
* Some of these representations occurred prior to Sam’s association with Gibson Dunn.
Capabilities
- Private Equity
- Emerging Companies / Venture Capital
- Life Sciences
- Mergers and Acquisitions
- Technology Transactions
Credentials
Education:
- BPP University - 2018 Postgraduate Diploma in Legal Practice
- University of Oxford - 2017 Bachelor of Arts
- The University of Sydney - 2012 Bachelor of Science
Admissions:
- England & Wales - Solicitor